Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 50%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Gossamer Bio is on track to submit seralutinib's NDA in September for the treatment of pulmonary arterial hypertension (PAH), and potential approval is expected in the third quarter of 2027. Management has emphasized the significant unmet need in PAH and the strong data package for seralutinib, with the potential to treat a substantial portion of the PAH patient population. The company has also addressed concerns about the liver enzyme elevation and cough side effects, and is pursuing an exchange offer to address the 2027 debt maturity wall. Overall, with a credible path towards FDA approval, the current valuation of Gossamer Bio may discount a near-terminal outcome, making it a good investment opportunity in the long term.

Bears say

Gossamer Bio is facing significant risks to achieving its price target of $5 per share due to its low probability of success for its lead product seralutinib in treating PAH and PH-ILD, dilution risk from potential future capital raises, and potential disruptions to its clinical trials due to ongoing conflicts in Eastern Europe. The company's recent financial results have also fallen short of expectations, and although it has enough cash to sustain operations, its future revenues may be uncertain. Overall, these fundamental factors contribute to a negative outlook on Gossamer Bio's stock.

GOSS has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 6 analysts, GOSS has a Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.